Eli Lilly has started dosing patients in the world's first trial for a medicine specifically designed to attack SARS-CoV-2, the virus that causes COVID-19.
The COVID-19 pandemic has brought many changes to the pharmaceutical industry, among them how companies can continue to engage with healthcare professionals (HCPs) and other stakeholders.
Like all UK pharma GMs working during the COVID-19 pandemic, Teva’s Kim Innes has found herself leading her company through an unprecedented crisis in one of the worst-hit countries in the
